SCHEMBL8966059

SCHEMBL8966059

N#Cc1cccc(-c2cncc(C(=O)c3cccc(N4CCNC(c5ccccc5)C4)n3)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 8/20 0.53
BRD4 O60885 1/20 0.43
BRD2 P25440 1/20 0.43
PRKCD Q05655 1/20 0.40
CYP11B2 P19099 1/20 0.39
GSK3B P49841 4/20 0.38
DGAT2 Q96PD7 1/20 0.38
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
SCD O00767 1/20 0.37
SCD5 Q86SK9 1/20 0.37
NAPEPLD Q6IQ20 1/20 0.36
DPP4 P27487 1/20 0.36
RPS6KB1 P23443 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8966003 0.93 PRKCQ (0.53) PRKCQPRKCDGSK3BSCD5NAPEPLD
SCHEMBL15930692 0.92 PRKCQ (0.59) PRKCQPRKCDGSK3BNAPEPLDRPS6KB1
SCHEMBL8965919 0.89 PRKCQ (0.55) PRKCQBRD4PRKCDGSK3BNAPEPLD
SCHEMBL15930694 0.88 PRKCQ (0.60) PRKCQPRKCDGSK3BSCDSCD5
SCHEMBL15930693 0.88 PRKCQ (0.52) PRKCQPRKCDGSK3BSCD5NAPEPLD
SCHEMBL15930701 0.87 PRKCQ (0.59) PRKCQPRKCDGSK3BCYP2D6
SCHEMBL8966162 0.87 PRKCQ (0.53) PRKCQPRKCDCYP11B2GSK3BNAPEPLD
SCHEMBL15930691 0.86 PRKCQ (0.56) PRKCQPRKCDGSK3BNAPEPLDRPS6KB1
SCHEMBL8966170 0.86 PRKCQ (0.52) PRKCQBRD4PRKCDGSK3BCYP2D6
SCHEMBL15930702 0.85 PRKCQ (0.54) PRKCQPRKCDGSK3BNAPEPLDRPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221334-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221334-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 PRKCQ 38/4885BRD4 1026/4885BRD2 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.